Mazdutide
aka IBI362
GLP-1 / Metabolic
Mechanism
Mazdutide is a dual GLP-1 / glucagon receptor agonist licensed from Eli Lilly to Innovent Biologics for Greater China. Approved by China's NMPA in June 2025 for chronic weight management and in September 2025 for glycemic control in type 2 diabetes; NOT FDA-approved in the US.
Identification
Vendors selling Mazdutide
No vendor listings on file yet.
Research
No citations on file yet.